ZTS
Zoetis Inc
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 2013-02-01
$82.99
-0.19 (-0.23%)
last quote
Want the full multi-source brief on ZTS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$82.99
High
$83.73
Low
$81.53
Previous close
$83.18
Fundamentals
Market cap
$33.68B
P/E (TTM)
12.88x
P/S (TTM)
3.54x
P/B
16.65x
Gross margin
71.63%
Operating margin
34.38%
Net margin
27.49%
Rev growth (YoY)
1.41%
EPS growth (YoY)
4.59%
ROE
69.25%
52W high
$144.83
52W low
$68.77
Beta
0.65x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-05todaybefore market
Q3 2026EPS est $1.53Rev est $2327.1M
Recent SEC filings
CIK 1555280filing-language history →
Recent news
2026-10-28 → 2026-11-04
SeekingAlpha · 10h
Zoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued
Zoetis is emerging from a period of underperformance, with market expectations for Q3 and Q4 set notably low. Read why ZTS stock is a speculative Buy.
Yahoo · 21h
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.
Yahoo · 22h
Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics
Evaluate the expected performance of Zoetis (ZTS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Yahoo · 23h
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +8.33% and +5.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 1d
1 healthcare stock with impressive fundamentals and 2 we ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 33.2% over the past six months, topping the S&P 500 by 26.1 percentage points.
SeekingAlpha · 1d
Top 25 Attractive Dividend Stocks For November 2026
Yahoo · 1d
IDEXX Soars 20% on Beat-and-Raise Quarter: “Early Innings of a Broad-Based Innovation Cycle”
Key TakeawaysIDEXX Laboratories shares jumped 20% after a third-quarter beat and a raised 2026 outlook. New inVue Dx analyzers are driving recurring test revenue, with in-clinic consumables up 15% organically.
Yahoo · 1d
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial